MDR1 Gene Polymorphism and Chemotherapy Response in Hodgkin's Lymphoma
Author Information
Author(s): Mhaidat Nizar M, Alshogran Osama Y, Khabour Omar F, Alzoubi Karem H, Matalka Ismail I, Haddadin William J, Mahasneh Ibraheem O, Aldaher Ahmad N
Primary Institution: Jordan University of Science and Technology
Hypothesis
The study investigates the association between MDR1 C3435T polymorphism and susceptibility to Hodgkin lymphoma and response to ABVD chemotherapy.
Conclusion
MDR1 C3435T polymorphism is associated with Hodgkin lymphoma occurrence but not with the clinical response to ABVD chemotherapy.
Supporting Evidence
- The T allele frequency was significantly higher in Hodgkin lymphoma patients compared to controls.
- The study found no association between the C3435T polymorphism and response to ABVD chemotherapy.
- Patients with the TT genotype had a higher frequency in Hodgkin lymphoma cases.
- Demographic data showed a median age of 30 years for patients and 23.5 years for controls.
Takeaway
This study found that a specific gene change is linked to getting Hodgkin lymphoma, but it doesn't help predict how well patients will respond to treatment.
Methodology
The study analyzed 130 tissue samples from Hodgkin lymphoma patients and 120 healthy controls using PCR-RFLP to identify the C3435T polymorphism.
Potential Biases
Potential bias due to the use of paraffin-embedded tissues from patients rather than fresh samples.
Limitations
The study only examined one polymorphism and did not consider other potential genetic factors that may influence chemotherapy response.
Participant Demographics
130 Hodgkin lymphoma patients (median age 30, 55% male) and 120 healthy controls (median age 23.5, 54% male).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website